Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMed

Arrhythmogenic Cardiomyopathy: the Guilty Party in Adipogenesis.

Stadiotti I., Catto V., Casella M., Tondo C., Pompilio G., Sommariva E.

Narrative Review on Cardiovascular Disease, published in J Cardiovasc Transl Res (2017) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
J Cardiovasc Transl Res (2017)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
28983804
DOI
10.1007/s12265-017-9767-8

Abstract (original English)

Arrhythmogenic cardiomyopathy (ACM) is a genetic cardiac condition characterized by the replacement of the ventricular myocardium with fibro-fatty tissue, by arrhythmias and sudden death. Adipogenesis in ACM is considered an aberrant remodeling following myocardial loss. Which cell type(s) is (are) responsible for the adipose replacement is still matter of debate. A systematic overview of the different cells that have been, over time, considered as main players in adipose replacement is provided. The comprehension of the cellular component giving rise to arrhythmogenic cardiomyopathy substrate defects may represent both an essential tool for mechanistic studies of disease pathogenesis and a novel possible therapeutic target.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AdipogenesisAdipose TissueAnimalsArrhythmogenic Right Ventricular DysplasiaCell TransdifferentiationFibrosisHumansMyocardiumMyocytes, CardiacPhenotype

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research